Oral Ketamine vs Placebo in Patients With Cancer-Related Neuropathic Pain: A Randomized Clinical Trial

JAMA Oncol. 2018 Jun 1;4(6):870-872. doi: 10.1001/jamaoncol.2018.0131.

Authors

Marie T Fallon¹, Andrew Wilcock², Caroline A Kelly³, James Paul³, Liz-Anne Lewsley³, John Norrie⁴, Barry J A Laird¹

Affiliations

¹ Edinburgh Cancer Research Centre (IGMM), University of Edinburgh, Edinburgh, United Kingdom.
² Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, United Kingdom.
³ Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
⁴ Usher Institute, University of Edinburgh, Edinburgh, United Kingdom.

Abstract

This multicenter randomized clinical trial compares oral ketamine with placebo for treating neuropathic pain in patients with cancer.

Publication types

Comparative Study
Multicenter Study
Randomized Controlled Trial

MeSH terms

Aged
Analgesics / adverse effects
Analgesics / therapeutic use*
Antineoplastic Agents / adverse effects
Anxiety / etiology
Cancer Pain / chemically induced
Cancer Pain / drug therapy*
Cancer Pain / psychology
Cognition Disorders / chemically induced
Depression / etiology
Double-Blind Method
Fatigue / chemically induced
Female
Gastrointestinal Diseases / chemically induced
Humans
Ketamine / adverse effects
Ketamine / therapeutic use*
Male
Middle Aged
Neuralgia / chemically induced
Neuralgia / drug therapy*
Neuralgia / psychology
Quality of Life

Substances

Analgesics
Antineoplastic Agents
Ketamine

Grants and funding